This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor.—
We read with great interest the article by Bhatia, Neely, and Wilson1 published in Pediatrics. The article suggests a simple and accurate method for assessing efficacy of gonadotropin-releasing hormone (GnRH) analog treatment of central precocious puberty (CPP). Although the GnRH stimulation test, intravenous or subcutaneous, is still considered the standard method for assessing therapeutic efficacy of CPP treatment, it is expensive, time-consuming, and uncomfortable for the patient. Therefore, in addition to clinical follow-up, in the last few years several alternative laboratory methods of monitoring therapeutic efficacy for children receiving GnRH agonist treatment have been proposed.
A few years ago we demonstrated that a single blood sample, obtained 12 hours after home injection of long-acting triptorelin, in children treated for CPP, provides a simple, convenient, comfortable, and inexpensive method for assessing efficacy of the treatment.2 We were disappointed when we read the author’s comments, referring to our article, stating “sampling 12 hours after the treatment dose is inconvenient as well as unnecessary.” Our …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Purchase access
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.